



**Clover Corporation Limited**

ABN 85 003 622 866

**ASX ANNOUNCEMENT**

**22 September 2025**

## **Clover Reports Strong Second Half Performance for FY25**

**Results for the year ended 31 July 2025**

Clover Corporation, a leading provider of innovative nutritional ingredients, is pleased to share its financial results for the fiscal year 2025 (FY25). The Company saw an improved performance throughout FY25, rebounding from the prior year.

- Net Sales Revenue in FY25 of \$86.0m in line with updated guidance (FY24: \$62.2m) a 38% increase on the prior year.
- 2H revenue of \$48.4m (1H \$37.6m) an increase of 38% on the same period prior year.
- Net Profit after Tax FY25 \$7.0m (FY24: \$1.5m)
- Growth in newer products has underpinned the top line with improved gross margins
- Continued improved performance by Melody Dairies (New Zealand supply point)
- Ecuador crude tuna oil facility now at 60% capacity
- Clover declares a final dividend of 1 cent per share for FY25

### **Clover Corporation CEO Peter Davey said:**

*"The Company has delivered a strong turnaround in performance with revenue increasing 38% to \$86m, improved profitability, and a more diversified earnings base. The final quarter revenue also set a new company record, reflecting strong seasonal demand. Our result this year is reflected in the management team's disciplined execution of the core business whilst servicing new customers with our broader product offering."*

*"The growth was supported by customer product launches across Asia and Europe, with customers increasingly adopting our innovative products contributing to improved margins".*

*"Operational performance improved across the business, with Melody Dairies achieving higher production volumes and lower unit costs, while our Ecuador facility is now a significant supplier of quality crude oil at competitive prices in a constrained market".*

*“The Company has continued broadening the distribution model during the year, with dedicated distributors appointed across key markets to manage marketing, inventory, and warehousing. This approach is already expanding our reach in North America, Asia, and Europe and positions us well for future growth”.*

#### **Strategic Developments:**

- Powdered CholineXcel : Ongoing trials to address commercial production volumes will continue through FY26, whilst our customers perform their own trials in use.
- Premneo Product Commercialisation: EU and ANZ is under further expert review. Clover continues to pursue regulatory approvals.
- Probiotic extended shelf-life testing is continuing.
- Continued investment in a product pipeline to access new markets and opportunities.

#### **Balance Sheet & Operating Cash Flows**

Strong cash generation from sales and working capital management, has been used to further pay down debt over the past 12 months. Commenting on the FY25 results, Peter Davey, CEO & Managing Director stated, “future cash flow generation looks promising with minimal debt, allowing Clover to continue focussing on investment in product, market and talent development”.

#### **Dividend:**

Based on the Company’s underlying performance and closing cash position, the Directors have declared a fully franked final dividend for FY25 of 1.0 cent per share. Relevant dates for the dividend are as follows:

- Ex-dividend Date: Monday, 20 October 2025
- Record Date: Tuesday, 21 October 2025
- Payment Date: Thursday, 20 November 2025

#### **Outlook:**

Based on the current market and global conditions, the Board expects 1H FY26 to be in line with 1H FY25.

#### **For further information, please contact:**

Mr Rupert Harrington – Chairman, Clover Corporation +61 3 8347 5000

Mr Peter Davey – MD & CEO, Clover Corporation +61 3 8347 5000

#### **About Clover Corporation Limited**

Clover Corporation is an Australian company listed on the Australian Stock Exchange (ASX:CLV). Clover evolved from being a research and development, manufacturing, and

marketing company to one concentrating on forming strategic relationships focused on technology, new product development and commercialisation.

Clover's superior microencapsulation technology enables nutritional oils, such as tuna, fish, algal and fungal oils, to be added to infant formula, foods and beverages. Developed through extensive research and development, our proprietary technologies protect those sensitive oils from oxidation, allowing them to be incorporated into a range of applications. All Clover products reach the highest standards of purity, stability, and performance, allowing customers to maximise and deliver nutrition.

For more information about Clover visit [www.clovercorp.com.au](http://www.clovercorp.com.au)